Walaiphorn Woraharn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Walaiphorn Woraharn has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Alec C. McDonald
Beatson West of Scotland Cancer Centre 8 , Glasgow, United Kingdom
8 shared publications - Annabelle Smith
University of Glasgow 7 School of Infection and Immunity, College of Medical, Veterinary and Life Sciences Glasgow, United Kingdom
8 shared publications - Ashley Kathryn McCulloch
Wolfson Wohl Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Bearsden, UK
8 shared publications - Aula Ammar
School of Cancer Sciences, Wolfson Wohl Cancer Research Centre University of Glasgow Glasgow UK
8 shared publications - Campbell Stuart Roxburgh
School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom
8 shared publications - Chia Yew Kong
Academic Unit of Surgery and Lister Department of Surgery, Glasgow Royal Infirmary University of Glasgow Glasgow UK
8 shared publications
Latest Publications
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Average C-reactive protein at each timepoint, in each treatment group
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Average C-reactive protein at each timepoint, in each treatment group
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Concentrations of cytokines in peripheral blood
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Concentrations of cytokines in peripheral blood
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Individual patient microenvironment cell population counter scores
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Individual patient microenvironment cell population counter scores
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Analytes for Bioteche 25-plex Immunopathology Multiplex Cytokine Assay
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Analytes for Bioteche 25-plex Immunopathology Multiplex Cytokine Assay
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Drug names and dosing schedules
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Drug names and dosing schedules
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Waterfall plots representing change in lymphocyte concentrations.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Waterfall plots representing change in lymphocyte concentrations.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Study representativeness table
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Study representativeness table
- 9 January 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (6) , 1145-1156
Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Purpose: Two dominant neoadjuvant radiotherapy (RT) regimens are in common use for locally advanced rectal cancer (LARC): long-course RT (LCRT; 25 × 1.8 Gy) with concomitant chemotherapy and short-course RT (SCRT; 5 × 5 Gy), typically followed by systemic chemotherapy. This study uses serial sampling to investigate the evolution of systemic and local immune responses to different RT regimens in LARC. Experimental Design: We conducted a serial sampling study involving patients receiving RT for LARC, in which longitudinal blood and tumor biospecimens were collected at baseline and at 2, 6, and 12 weeks after treatment initiation. Leukocyte concentrations via full blood count and a multiplex cytokine ELISA of plasma samples measured systemic changes. Multiplex immunofluorescence (CD8 and FOXP3) and RNA sequencing of tumor biopsies were used to assess local changes. Results: Circulating lymphocyte concentrations tended to increase in SCRT patients and decrease in LCRT patients between week 2 and week 6 and were significantly lower in LCRT patients compared with SCRT patients at week 6 (P < 0.0001) and week 12 (P = 0.019). Additionally, we report higher densities of CD8+ and FOXP3+ tumoral lymphocytes from SCRT patients compared with LCRT patients at week 2 (CD8 P = 0.053; FOXP3 P = 0.023) and week 6 (CD8 P = 0.035; FOXP3 P = 0.0016). Conclusions: SCRT is less lymphodepleting and induces more frequent increases in intratumoral T-cell infiltration compared with LCRT. These results are relevant to the field of radiation–immune-oncology combination studies in LARC. Furthermore, these findings may underpin early trial results, in which higher rates of response to RT–immune checkpoint inhibitor combinations have been reported with SCRT-based regimens.
- 9 January 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (6) , 1145-1156
Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Purpose: Two dominant neoadjuvant radiotherapy (RT) regimens are in common use for locally advanced rectal cancer (LARC): long-course RT (LCRT; 25 × 1.8 Gy) with concomitant chemotherapy and short-course RT (SCRT; 5 × 5 Gy), typically followed by systemic chemotherapy. This study uses serial sampling to investigate the evolution of systemic and local immune responses to different RT regimens in LARC. Experimental Design: We conducted a serial sampling study involving patients receiving RT for LARC, in which longitudinal blood and tumor biospecimens were collected at baseline and at 2, 6, and 12 weeks after treatment initiation. Leukocyte concentrations via full blood count and a multiplex cytokine ELISA of plasma samples measured systemic changes. Multiplex immunofluorescence (CD8 and FOXP3) and RNA sequencing of tumor biopsies were used to assess local changes. Results: Circulating lymphocyte concentrations tended to increase in SCRT patients and decrease in LCRT patients between week 2 and week 6 and were significantly lower in LCRT patients compared with SCRT patients at week 6 (P < 0.0001) and week 12 (P = 0.019). Additionally, we report higher densities of CD8+ and FOXP3+ tumoral lymphocytes from SCRT patients compared with LCRT patients at week 2 (CD8 P = 0.053; FOXP3 P = 0.023) and week 6 (CD8 P = 0.035; FOXP3 P = 0.0016). Conclusions: SCRT is less lymphodepleting and induces more frequent increases in intratumoral T-cell infiltration compared with LCRT. These results are relevant to the field of radiation–immune-oncology combination studies in LARC. Furthermore, these findings may underpin early trial results, in which higher rates of response to RT–immune checkpoint inhibitor combinations have been reported with SCRT-based regimens.